mir-188‐5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-10359-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Osman Akidan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Mengücek Gazi Education and Research Hospital, Erzincan, Turkey. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, MicroRNAs, Small Ubiquitin-Related Modifier Proteins, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Chronic myeloid leukemia (CML) is an aggressive malignancy originating from hematopoietic stem cells. miRNAs play a role in physiological and developmental processes, including cellular proliferation, apoptosis, angiogenesis, and differentiation, and in CML's prognosis, diagnosis, and treatment. This study aimed to investigate the function and possible mechanisms of action of miR-188-5p in the development and progression of chronic myeloid leukemia. METHODS AND RESULTS: miRNA expression profiles were obtained from the GSE90773 dataset in the Gene Expression Omnibus (GEO). GEO2R was used to identify differentially expressed miRNAs. miRNET, miRDB, CancerSEA, GeneMANIA, and BioGRID databases were applied to assess the biological function of miRNA and target molecules in CML. RT-PCR performed validation analyses of miRNA and target molecules in CML. To determine the power of miR-188-5p expression levels to distinguish patients with CML from control, the ROC analysis was performed. miR-188-5p is significantly increased in K-562 cells, and overexpression of miR-188-5p was associated with clinicopathological features. miR-188-5p showed significantly higher AUC values (AUC = 1.0, p = 0.0001). The cut-off of miR-188-5p was 6.74. miRDB and mirNET predicted BUB3 and SUMO2 as a potential target gene of miR-188-5p. Additionally, increased expression of BUB3 and SUMO2 was observed in the K-562 cell. Bub3 is implicated in apoptosis and the cell cycle, whereas Sumo2 protein sumoylation and DNA binding are believed to contribute to catabolic processes. CONCLUSIONS: Our results suggest that miR-188-5p acts as an oncomiRNA in CML pathogenesis and may be a promising therapeutic target for CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Mengücek Gazi Education and Research Hospital, Erzincan, Turkey.
- Laboratory for Radiobiology and Molecular Genetics, "VINČA" Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, Belgrade, 11000, Serbia.
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, 11000, Serbia.
- Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Turkey. smisir@cumhuriyet.edu.tr.
Zitieren
APA
Akidan, O., Petrovic, N., & Misir, S. (2025). mir-188‐5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10359-9
Vancouver
Akidan O, Petrovic N, Misir S. mir-188‐5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10359-9
BibTeX
@article{Akidan2025,
author = {Akidan, Osman and Petrovic, Nina and Misir, Sema},
title = {mir-188‐5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-10359-9}
}
EUVIMED